Journal of hepato-biliary-pancreatic sciences · 2026
Relative Dose Intensity and Outcomes in Elderly Patients With Resectable Pancreatic Cancer Receiving Neoadjuvant Chemotherapy.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Takeda Tsuyoshi, Ozaka Masato, Sasaki Takashi, Inoue Yosuke, Hirai Tatsuki, Mie Takafumi, Furukawa Takaaki, Okamoto Takeshi, Takahashi Yu, Sasahira Naoki
Аннотация
BACKGROUND: Neoadjuvant chemotherapy (NAC) with gemcitabine and S-1 (GS) is the standard regimen for resectable pancreatic cancer (PC) in Japan. However, its efficacy in elderly patients and those with impaired renal function remains unclear.
METHODS: We retrospectively analyzed patients with resectable PC who received NAC GS. Patients were classified as elderly (≥ 75 years) or non-elderly (< 75 years). The primary endpoint was relative dose intensity (RDI) of NAC. Secondary endpoints included adverse events (AEs), perioperative outcomes, RDI of adjuvant chemotherapy (AC), recurrence-free survival (RFS), and overall survival (OS).
RESULTS: A total of 185 patients were included (non-elderly: 148, elderly: 37). Median creatinine clearance (CCr) was lower in elderly patients (64.2 vs. 84.5 mL/min, p < 0.001). Mean RDI of GS was significantly lower in elderly patients and those with CCr < 50 mL/min, particularly when both factors coexisted. Severe hematologic AEs were more frequent in these groups, though perioperative outcomes were similar. While initiation of AC was delayed and RDI of adjuvant S-1 was lower in elderly patients, RFS and OS did not significantly differ between groups.
CONCLUSIONS: NAC GS appears feasible in elderly patients with resectable PC, though caution is needed in those with impaired renal function.
METHODS: We retrospectively analyzed patients with resectable PC who received NAC GS. Patients were classified as elderly (≥ 75 years) or non-elderly (< 75 years). The primary endpoint was relative dose intensity (RDI) of NAC. Secondary endpoints included adverse events (AEs), perioperative outcomes, RDI of adjuvant chemotherapy (AC), recurrence-free survival (RFS), and overall survival (OS).
RESULTS: A total of 185 patients were included (non-elderly: 148, elderly: 37). Median creatinine clearance (CCr) was lower in elderly patients (64.2 vs. 84.5 mL/min, p < 0.001). Mean RDI of GS was significantly lower in elderly patients and those with CCr < 50 mL/min, particularly when both factors coexisted. Severe hematologic AEs were more frequent in these groups, though perioperative outcomes were similar. While initiation of AC was delayed and RDI of adjuvant S-1 was lower in elderly patients, RFS and OS did not significantly differ between groups.
CONCLUSIONS: NAC GS appears feasible in elderly patients with resectable PC, though caution is needed in those with impaired renal function.
Предметные рубрики MeSH
HumansPancreatic NeoplasmsNeoadjuvant TherapyRetrospective StudiesMaleAgedFemaleDeoxycytidineTegafurGemcitabineOxonic AcidChemotherapy, AdjuvantTreatment OutcomePancreatectomyDrug CombinationsJapanMiddle AgedDose-Response Relationship, DrugAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsAge FactorsAntimetabolites, AntineoplasticSurvival Rate